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ABSTRACT 
 Three different studies set forth to investigate the role of phosphodiesterase (PDE) 
enzyme inhibitors in sexual dysfunction and mood regulation.  First, natural products were 
screened by computer modeling of PDE5A1.  Second, compounds were isolated from a plant 
traditionally used as an aphrodisiac. Third, a new synthesis of psychoactive PDE4 inhibitor was 
attempted.     
 An in silico screen was performed using chemical structures of isolated compounds 
thought to have some PDE inhibitory activity based on traditional use of the plants.  A collection 
of compounds with structures similar to known natural product inhibitors was also included in 
the docking library.  Glide docking software (Schrödinger) was used to score compounds based 
on their modeled interactions with the PDE5A1 enzyme.  The compounds that showed the best 
scores were assayed for in vitro PDE inhibitory activity.  Enzymatic screening suggested some 
inhibition of PDE5A1 by selected compounds. Four of seven compounds showed greater than 
70% inhibition at 100 μM concentration. 
 Tongkat ali (Eurycoma longifolia Jack) root material was subjected to chromatographic 
separations in an attempt to discover new PDE inhibitors.  Only known terpenes, sterols and 
alkaloids were identified.  However, one new x-ray crystal structure of a sterol previously 
unreported in E. lonigfolia was determined.     
 Mesembrine, a known alkaloidal PDE inhibitor, has been a subject of many synthetic 
studies.  A synthetic route was initiated using a diastereoselective Michael addition reaction to 
generate the target quaternary center.  
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CHAPTER 1 
IN SILICO GUIDED SCREENING OF PDE5A1 INHIBITORS 
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1.1 Introduction 
 The ubiquity of phosphodiester bonds in all living organisms indicates the importance of 
these bonds to various areas of basic biological and medical research.  The highest 
concentrations of these bonds are used for the long-term storage and transmission of information 
within cells and between generations in the form of Deoxyribonucleic Acid (DNA) and  
Ribonucleic Acid (RNA).  In DNA and RNA, these bonds serve to link the 3ʹ and 5ʹ positions of 
adjacent ribose units.  Phosphodiester bonds are essential to maintaining the integrity of three 
billion base pairs of human nuclear DNA.
1
  Aside from  their obvious structural significance in 
maintaining genetic information, phosphodiester bonds are present in phospholipids, 
sphingolipids and cyclic nucleotides. Of all these types, it is the set of enzymes that hydrolyzes 
phosphodiester bonds in cyclic nucleotides that is denoted the title of “phosphodiesterases” 
(PDEs).
1
  
 As primary signaling metabolites are distributed across tissues of an organism, they are 
differentially translated into secondary messengers when membrane-bound receptors activate 
internal enzymes. 
1
  By converting primary messengers into secondary messengers, signals are 
selectively transferred to different regions of the body and amplified or diminished based on the 
target of the secondary signal.  In the case of PDE enzymes, the broadest distinguishing 
characteristic is their preference for cAMP or cGMP.  Within the superfamily of 
phosphodiesterases, there are 11 families known to exist in mammals.  The enzymes specific for 
cAMP include PDE4, 7, and 8.  Those specific for cGMP include PDE 5, 6, 9.  PDEs 1, 2, 3, 10 
and 11 are active on both cyclic nucleotides. 
2
 Within these 11 PDEs there are many splice-
variants, each of which potentially adopting multiple folded conformations.  Taking together all 
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possible structural variations along with their different tissue distributions, phosphodiesterases 
have proved to be an alluring area for biochemists, molecular biologists and pharmaceutical 
researchers alike.    
 
1.2 Structure of Phosphodiesterases and the Therapeutic Role of their Inhibitors 
Signaling and Structure 
 Cyclic nucleotides are ubiquitous second messenger molecules, serving to integrate 
various intra- and extraorganismal signals (neurotransmitters, hormones, tastes, odors, and light) 
into a unified chemical format.  cAMP and cGMP are formed by purine cyclases. In the case of 
adenyl cyclases (ACs), transduction of this secondary signal is initiated when G-protein coupled 
receptors (GPCRs) receive some primary signal. This leads to activation of heterotrimeric G-
protein, with the Gαs subunit bearing responsibility for activation of all but one adenyl cyclase 
(AC10) isozymes.  On the other hand, guanyl cyclases (GCs) are divided into soluble and 
membrane-bound, receptor-coupled classes.  Soluble GCs are activated by nitric oxide and 
receptor-bound GCs are activated by natriuretic peptide hormones. 
3
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Substrate PDE isoform 
Both adenine/ guanine 1, 2, 3, 10, 11 
cAMP only 4, 7, 8 
cGMP only 5, 6, 9 
Table 1: Nucleotide  specificities of phosphodiesterase family. 
 As the concentrations of cyclic nucleotides rise within the cell, binding to their targets, 
protein kinase A (PKA) and protein kinase G (PKG) are enhanced.  These protein kinases, in 
turn, phosphorylate downstream targets such as ion channels and transcription factors.  The 
reverse of this cyclization process is hydrolysis of the PDE bond by phosphodiesterases, and  the 
rate of formation  or degradation of these cyclic nucleotides affects the overall activation of this 
signaling pathway.
4
 
 Molecular studies have elucidated 11 distinct families of phosphodiesterases which are 
grouped according to their cyclic nucleotide monophosphate substrates.  PDEs 4, 7 and 8 
hydrolyze cAMP whereas PDEs 5, 6 and 9 hydrolyze cGMP.  PDEs 1, 2, 3, 10 and 11 are 
capable of hydrolyzing both substrates (Table 1).  Because the cyclic nucleotide signaling system 
is globally distributed in organisms, there is broad potential of pharmacological investigation 
into the various processes including, proinflammatory response, muscle relaxation, ion channel 
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function, apoptosis, cellular differentiation, learning, memory and essential metabolic processes 
of gluconeogenesis, glycogenolysis and lipogenesis.
5
 
 
Figure 1: GMP signaling system overview. 
3
 
  
 In the late 1970s,  chemists began to produce small molecules which could inhibit 
kinetically distinct PDEs.  Based on these findings, research into the area expanded to the  
present day and PDEs are considered to hold potential for treatment for various health problems 
including heart failure, depression, cognitive decline, asthma, COPD, inflammation and erectile 
6 
 
 
dysfunction.
5-6
 There are many unmet medical needs which may benefit from selective control of 
this critical signaling system.  To date, three PDE5 inhibitors, four PDE3 inhibitors and one 
PDE4 inhibitor have been approved by the FDA.  There are currently two PDE4 candidates 
awaiting approval, with 20 other small molecule inhibitors of PDE4 in clinical studies. 
7
  Part of 
this advance in the discovery, rational design and optimization of inhibitors can be traced to the 
elucidation of 3D structures derived from X-ray crystallographic studies.  The catalytic domains 
of PDE 1, 3, 4, 5, and 9 have been published and made publicly available to investigators.
8
   
 Despite their variable preference for cAMP versus cGMP, phosphodiesterases all bear the 
same three functional domains: the regulatory N-terminus, the conserved catalytic core and the 
C-terminus. 
9
  The regulatory N-terminal region is adjacent to the catalytic core.  Regulatory 
elements of N-terminal domains include an auto-inhibitory region and a targeting sequence to 
guide its cellular localization.  Within the N-terminal region there are various other regulatory 
elements depending on the isozyme. In PDE1, there is a calmodulin (CaM) binding domain;  
PDE2 contains multiple cyclic guanosine monophosphate binding sites;  PDEs 1-5 all contain 
phosphorylation sites for distinct protein kinases; and PDE6 also bears a transducin binding 
site.
10
   
 The most studied domain of the PDE enzymes for drug discovery has been the conserved 
catalytic domain at the carboxylic terminus. It consists of 270 amino acids with sequence identity 
ranging from 18-46% across the various isoforms. 
2
 The catalytic domain structures of PDE5A, 
PDE4B, PDE4D, PDE1B, PDE3B and PDE9A have all been reported from crystallographic 
studies.  Within this catalytic domain are three subdomains comprised of helices: the N-terminal 
cyclin-fold, a linker portion and a C-terminal helical region. 
8b, 8c, 8e, 8f, 8h, 8i
   At the junction of 
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these subdomains, a deep hydrophobic pocket is formed with four distinct sites.  Within this 
pocket lies a core pocket (Q pocket), a lid region (L region), the hydrophobic pocket (H pocket) 
and the metal-binding site (M site). 
8f
  
 
Figure 2: The phosphodiesterase enzymes' core pocket with four conserved areas 
8f
 
 
 Within the M site, various metal atoms are bound to fully conserved residues across the 
entire PDE family.  Based on the coordination geometry of the coordinating ligands, the metals 
present in the M site are thought to be zinc and magnesium ions.  The metals ions exhibit 
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octahedral coordination geometry.  The zinc ion is coordinated by one aspartate and three 
histidine residues, as well as two water molecules.  Magnesium is coordinated to the same 
aspartate residue, and five water molecules.  One water molecule is shared with zinc.  The metal 
ions are thought to aid in the stabilization and activation of hydroxide in catalysis. 
8i
        
 The Q pocket seems to interact with ligands through hydrogen-bonding with conserved 
glutamine residues as revealed in the PDE5A crystal structure complex with the 
pyrazolopyrimidinone core of sildenafil.  The glutamines are present on both sides of the Q 
pocket providing extra stabilization in a clamp-like manner.
8i
 
 The hydrophobic H pocket can accommodate alkoxyphenyl residues such as the 
ethoxyphenyl, cyclopentoxyphenyl, and methoxyphenyl moieties of sildenafil, rolipram and 
mesembrine, respectively.  It is the variation of residues within this H pocket which confers 
selectivity to particular phosphodiesterases.  It is the flexibility of the L region of PDE5A in the 
Tyr664/Met816/Ala823/Gly819 residues which allows for a conformational fluctuation between 
open and closed forms to control binding of different inhibitors.
2, 8i
   
 Of the many structure features observed in phosphodiesterase enzymes to differentiate 
between substrates, the most critical seems to be the ‘glutamine switch’ functionality.8i  The 
proposed mechanism suggests that a conserved glutamine residue plays a critical role in PDE 
nucleotide selectivity.  There are two potential orientations that the γ-amino group of the 
glutamine residue in the active site may adopt to establish different hydrogen-bonding relays.  In 
the example of endogenous PDE substrates, one orientation will support guanine binding and 
preferentially process cGMP.  In the opposite orientation, glutamine will establish a hydrogen-
bonding network where adenine will be supported, making cAMP the preferred substrate.  In 
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PDEs 1, 2, 3, 10 and 11, the side chain may adjust its orientation to accommodate both cyclic 
nucleotides.  
 
Figure 3: “Glutamine switches” in various PDEs. [2] 
 
 As displayed in Figure 3, members of the phosphodiesterase family respond differently to 
different substrates based on a conserved glutamine residue “switch mechanism”.  In images (A) 
and (B), PDE1B recognizes AMP and GMP, respectively.  His381 and His373 allow for 
substrate interaction with Glu421.   In images (C) and (D), Glu988 of PDE3B accommodates 
either cyclic nucleotide because His948 is occupied by interactions with Trp1072, allowing 
either Glu988 orientation.  In PDE4D (E), a hydrogen-bonding relay is created between Asn321, 
Tyr329, Glu369, and the exocyclic amine moiety of the adenine substrate.  On the other hand, 
there appears to be an inversion of orientation in the Glu817 residue in PDE5A1 (F) co-
crystallized with GMP.  A well-ordered hydrogen-bond relay is established between Ala767, 
Glu775 and Trp853 with Glu817, effectively locking it in a conformation where only the γ-
10 
 
 
amide of Glu817 can interact with the exocyclic O-atom of guanine substrates.  In the case of 
PDE9A (G), GMP is again the preferred substrate, this time due to hydrogen-bond relay between 
Gln406 and Ser486 with invariant Glu453.    
 The aforementioned structural features of PDE enzymes correspond to three general 
features of PDE ligands.  First, the central rings of the purine moiety must interact with the 
invariant glutamine via single or dual hydrogen-bonds.  Second characteristic of favorable PDE 
ligands is the ability of core rings to interact with the nonpolar side chains of residues in 
‘hydrophobic clamp’ region.  In the case of PDE5A, this feature contributed significantly to 
reduction in side-effects between first and second generation inhibitors.  While sildenafil does 
interact with hydrophobic residues, its seven rotatable bonds create steric hinderance and require 
entropic loss to become situated in the clamp.  Tadalafil, conversely, is considerably more rigid 
with only one rotatable bond that allows for fewer collisions as it approaches the hydrophobic 
clamp.  The third notable feature is that substrates interact with metal ions whereas inhibitors 
have not demonstrated this interaction. 
2
   
Therapeutic developments of PDE inhibitors 
Sexual function 
  The FDA approval of Viagra (sildenafil) in 1998, followed by its market success, 
generated a great deal of attention for what is undoubtedly the most famous PDE inhibitor.  In 
fact, it has become one of the most famous drugs in history.  It implied that sexual dysfunction 
may be overcome through modern medicine.  As a drug, however, it does not function as an 
‘aphrodisiac’ in the traditional sense.  Sildenafil action follows the initially arousing stimuli 
11 
 
 
(touch, smell, sight, fantasy, etc.), and nitric oxide (NO) is released from neurons and endothelial 
cells in the penis.  This NO released into cells activates the soluble guanyl cyclases, leading to a 
PKG-mediated phosphorylation cascade. 
11
   The ensuing decrease of Ca
2+
 leads to an arterial 
dilation and compression of corpus cavernosum tissue of the penis.  As blood becomes trapped in 
the penis, intracavernosal pressure increases and erections manifest.
12
  In the case of sildenafil, it 
is not the activation of guanyl cyclase, but the inhibition of PDE5A1 that enhances cGMP 
concentration.  The success of Viagra spawned two similar PDE5 inhibitors, Cialis (tadalafil) 
and Levitra (vardenafil), and aroused interest in researching whether a similar approach may 
work for female sexual dysfunction (see Figure 4).  The clitoris and anterior vaginal wall 
contains erectile tissue similar to those of the penis.
13
  The presence of nitric oxide synthase 
(NOS) and PDE5 enzyme in the clitoral corpus cavernosum suggest a common physiological 
mechanism of male and female arousal. 
14
  A double-blind, placebo-controlled crossover-design 
study by Caruso et al. showed that sildenafil improved sexual arousal, orgasm, frequency of 
sexual fantasies and frequency of sexual intercourse in premenopausal females. 
15
 Tadalafil, 
however, demonstrated no conclusive therapeutic effects compared with a placebo in a 2001 
phase I clinical trial, exploring its use in women with female sexual arousal disorder. It remains 
to be seen whether this area will prove helpful for women suffering from sexual dysfunction.  
12 
 
 
 
Figure 4:PDE5A inhibitors marketed for erectile dysfunction. 
 
Respiratory inflammation 
  While the majority of attention has been paid to PDE inhibitors for erectile dysfunction, 
there has also been active development of drugs for treatment asthma and chronic obstructive 
pulmonary disorder (COPD).  In rabbit, guinea pig and monkey models, pretreatments with 
PDE4 inhibitors diminished the level of antigen-induced bronchoconstriction and eosinophil 
infiltration. 
16
  These studies also demonstrated a reduction in both pulmonary microvascular 
leakage and airway reactivity.
16b, 16d, 16e
  The perceived benefit of these compounds over existing 
drugs is that they are capable of relaxing airways as well as diminishing underlying airway 
inflammation.  The PE4 inhibitor roflumilast (Daliresp) was approved by the FDA in 2011 for 
treatment of COPD.
7
  The next  most promising candidate  is cilomilast (Ariflo), currently in a 
Phase III clinical trial.  
13 
 
 
 
Figure 5:PDE4 inhibitors investigated for COPD and asthma. 
 
Central Nervous System 
 The last major area to be addressed is the connection of mood and cognition to 
phosphodiesterase signaling.  The focus of research has largely involved neurodegeneration-
associated cognitive decline and depression.  Kakkar et al. provided evidence that brain-specific 
PDE1A2 was inhibited by the antiparkinsonian drugs selegiline and amantadine, enhancing 
intracellular levels of cAMP. 
17
 This suggests that PDE1 enzymes in the brain may be a possible 
target of future Parkinson’s disease treatments.  The semisynthetic compound vinpocetine, which 
inhibits PDE1 and shows potent anti-inflammatory activity through a separate mechanism has 
been considered as a treatment for neurodegenerative disorders.
18
     
14 
 
 
 
Figure 6: PDE1 (top row) and PDE4 (bottom row) investigated for cognitive function 
 
 Mutational analysis of cAMP response-element binding protein (CREB) has shown it to 
be a controlling factor in long-term memory formation.
19
  Transgenic Drosophila melanogaster 
(fruit flies) demonstrate creation of long-term memories after less behavioral training in groups 
with overexpressed CREB.
20
   This same ‘CREB-signature’ effect was shown in animals treated 
with the PDE4 inhibitor rolipram. 
21
  Rolipram has also been investigated in animals as a 
treatment for depression and memory loss.
22
   There is also evidence that cAMP affects neuron 
survival, potentially through regulation of brain-derived neurotrophic factor (BDNF) 
upregulation.
23
  Although mounting evidence supports the role of cAMP in neuronal survival and 
memory, the side-effects of rolipram have relegated it to “probe” status. 23d-f, 24 
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Natural Product PDE Inhibitor Examples  
 Mesembrine, mesembrenone (from Sceletium tortuosum), moracin A , moracin C (from 
Morus alba L.), theophylline (from Theobroma cacao).
25
 
 
Figure 7:Examples of natural product PDE inhibitors 
 
Phosphodiesterases inhibitors for erectile dysfunction  
The ability to maintain satisfactory sexual function is a notable problem which can 
impact interpersonal relationships and quality of life in otherwise healthy individuals.  The age-
old quest for aphrodisiacs has taken many forms.  A survey of literature on the subject turns up 
formulations which have been used to enhance arousal, function, stamina and fertility.  While 
‘arousal’ may be harder to define and test, function and fertility are slightly easier.  Perhaps the 
easiest to quantify is the male erection, which becomes more difficult to maintain as men age.  
During erection nitric oxide is released from parasympathetic nerve terminals into the smooth 
muscle cells of the corpus cavernosum.  Activation of guanyl cyclase converts guanosine 
16 
 
 
triphosphate (GTP) into cyclic guanosine monophosphate (cGMP).  This causes relaxation of 
smooth muscles, dilation of blood vessels and enhanced blood flow into the penis.  It is the 
trapping of this blood which results in erections, and the inhibition of the signaling molecule 
cGMP has shown to be a means of inducing erections in humans.  
The most notable drug working on phosphodiesterases to be developed and marketed thus 
far is sildenafil citrate (Viagra), which has greatest affinity on the PDE5A enzyme.  In 1985, 
chemists at Pfizer first began developing treatments for angina and hypertension by targeting 
PDEs which were fairly unexplored at the time.  Starting from Zaprinast, a known vasodilator 
working through PDE inhibition, Pfizer explored structure-activity relationships to enhance PDE 
selectivity.  In this time before combinatorial synthesis, the team of five chemists impressively 
generated 1,600 compounds over three years for screening.  Of this group compound UK-92480 
proved to be most selective for PDE5, with some activity at PDE6- an enzyme known to play a 
role in visual signal transduction.    As the compound entered into clinical trials, it was proven to 
not be effective for angina.  However, the clinicians did notice that the majority of patients on 
high doses “suffered” the side effect of improved erections.  Pfizer realized the opportunity to 
build off this effect and was able to successfully carry the drug through trials. 
26
 The compound 
UK-92480 was labeled Viagra and would become a blockbuster drug and widely recognized by 
name.  In the years that followed, vardenafil and tadalafil would also reach the market and share 
success as pro-erectile PDE inhibitors.  
 Despite all the success of these drugs, there remains the side-effects that where initially 
noticed in early development.  Partial activity at PDE6 is thought to contribute to some visual 
disturbances such as blue and green hues in the visual field.   For this reason, there is still 
17 
 
 
considerable room for improvement on these popular drugs.  Many plants have been traditionally 
used to help attain erection.  Figure 8 shows four extracts and three of the isolated components 
from these plants that have been screened for activity against human PDE5A1.
27
  Of this set, 
icariside II showed the greatest level of PDE inhibition.  To further investigate the ability of 
plants to inhibit phosphodiesterases, an in silico screening project was performed.  Using 
Schrödinger’s Maestro interface, the Glide docking module was trained using a PDE5A1 
structure co-crystallized with icariside II.  Plants used for docking were Epimedium spp., 
Lepidium meyenii Walp. (maca, Ginko biloba L., and Ferula hermonis Boiss.  In addition to 
these plants, previously isolated compounds bearing structural similarity to icariin would be 
included in the docking set.  
   
 
Figure 8:From Dell’Agli et al. (T.t.= Tribulus terrestris, E.b.= Epimedium brevicornum, C.c. Cinnamonium cassia,  
F.h. = Ferula hermonis, cinn. = cinnamaldehyde) [59] 
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Natural Prodcucts Used  
The Epimedium (Berberidaceae) genus has attracted much attention for their use as an 
aphrodisiac.  The plant goes by many names, including Rowdy Lamb Herb, Barrenwort, 
Bishop’s Hat, Fairy Winds, Horny Goat Weed, Yangheye and Yin Yang Huo.28  
Out of approximately 52 species, more than 15 species in this genus have been used historically 
to aid kidney function and to “reinforce the Yang”. The most commonly cited species for use as a 
sexual tonic are E. brevicornum, E. grandifolium and E. sagittatum.   The Chinese Pharmacopeia 
officially recognizes the five major Epimedium species as official sources of Herba Epimedii.  
These recognized species are:  Epimedium brevicornum Maxim, E. sagittatum (Sieb. and Zucc.) 
Maxim., E. pubescens Maxim., E. wushanese T.S. Ying and E. koreanum Nakai.
28
  In China and 
Japan, varieties have been used to treat impotence, prospermia, hyperdiuresis, osteoporosis, 
menopause, rheumatic arthritis, hypertension, and chronic tracheitis.  In Korea, E.koreanum was 
also used for impotence, as well as spermatorrhoea (involuntary ejaculation) and forgetfulness.
29
 
The chemistry of the plant has been well defined.  Isolated classes include flavonoids
30
, 
lignans, phenolic glycosides, phenylethanoid glycosides and seqsuiterpenes.  The greatest 
amount of pharmacological investigation has been in the prenylated flavonol glycosides.  
Notably, icariin has been shown to have activity (IC50 value of 5.9mM) at PDE5A1, the primary 
target for the popular pharmaceutical proerectile drugs vardenafil, tadalafil and sildenafil.
27
   The 
structure PDE5A1 has been co-crystallized with icariside II, a derivative of icariin which lacks a 
rhamnose unit at the 7-O position of the flavonol structure. 
 Ginkgo biloba L. , also referred to as yín xìng or the “maidenhair tree” has no known 
living relatives, for which people consider it to be a living fossil of sorts.  Originally from China, 
it was introduced to North America by André Michaux.
31
  These trees can grow to over 30 
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meters in height and is known to display erratic branching patterns.  Individual trees are known 
to live over 1000 years and reproductive organs emit a foul odor due to its butyric acid content.
32
  
During to the extensive relationship and the significance of the plant in East Asia, it served many 
roles and as a food and medicine.  The plant has been used in Asia traditionally for various 
indications. Extracts of the ginkgo plant and isolated compounds have been assayed in humans 
and other animals to better understand its therapeutic potential.    The characteristic constituents 
of the plant are ginkolides and flavonoids (See Figure 9). Whole plant material and extracts 
thereof have shown activity in extensive animal studies and over 120 published clinical trials.  
The most common standardized extract EGb 761, or variations which contain the same 
proportion of flavonoid glycosides, terpene lactones and ginkgolic acids have been used in many 
of these trials.  The most promising results were shown in anti-aggregant, anti-oxidant, 
neuroprotective, altitude sickness, Alzheimer’s disease, dementia, intermittent claudicating, 
dysmenorrheal and vertigo assays. 
33
  In a study investigating the memory enhancing potential of 
G. biloba on geriatric patients, it was observed that many patients experienced improved 
erections.  In a follow-up study, Cohen and Bartlik reported G.biloba had a positive effect “on all 
four phases of the sexual response cycle: desire, excitement (erection and lubrication), orgasm 
and resolution.” 34  Patients of this group had all previously “exhibited sexual dysfunction 
secondary to a variety of antidepressant medications including selective serotonin reuptake 
inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors and 
tricyclics.”  
20 
 
 
 
Figure 9: Example of compounds from G. biloba used in in silico docking 
 
 Ferula hermonis Boiss. (Umbelliferae) is a plant native to mountainous regions of the 
Middle East, including Lebanon and Syria.  Its name refers to Mt. Hermon, upon which it grows.  
The notable marker compounds of the plant are daucane sesquiterpenes.  The large genus Ferula 
encompasses 150 species.  Some species within this genus have been used traditionally for skin 
infections, headache, arthritis, digestive disorders, dysentery, and as an aphrodisiac and 
antihysteric.  Claims of usefulness for impotence are supported in Arabic medical literature.
35
  
Although somewhat rare, the root material can be found for sale, sometimes advertised as 
“Lebanese Viagra” by internet retailers.   Research to better understand the aphrodisiac activity 
of F. hermonis has demonstrated that it increases the sexual activity of male rats.
36
  Ferutinin has 
shown potent phytoestrogenic activity at the human estrogen receptor.
37
  In a study by Colman-
Saizarbitoria, ferutinin also exhibited the ability to “increase nitric oxide synthase activity and 
inositol monophosphate accumulation in the median eminence of the rat brain”.38  This suggests 
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a potential role in neuroendocrine regulation, but possibly activity in nitric oxide regulation in 
other tissues.   
 
Figure 10: Example of compounds from F. hermonis used in in silico docking 
 
 
 Lepidium meyenii  Walpers (Cruciferae) is widely sold as a dietary supplement and 
functional food under the name “maca”.  The preferred plant part is the hypocotyls, which was 
traditionally consumed by humans and livestock largely within the Meseta de Bombon, Peru.  
Although initially from an area of high altitude (3700-4500 above sea level) and intense winds, 
the plant has been successfully cultivated outside its native habitat.  It has thus been suggested by 
Chacon that the domesticated form be regarded separately as L. peruvianum Chacon.
39
  The plant 
has been held in high regard since pre-Incan times and during the Incan Empire it was consumed 
only by members of nobility rewarded to warriors. 
40
  Aside from being used in foods and 
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beverages, there have been claims that maca enhances fertility and sex-drive.   Although studies 
have shown it does not exert its purported effects through a direct androgenic effect, other 
evidence shows significant alleviation of SSRI-induced sexual dysfunction in women.
41
 
 The remaining portion of the Glide screening set were compounds previously isolated 
from microbial transformation.  In this method, organisms were selected from a group of 40 
culture samples from National Center for Natural Products Research at The University of 
Mississippi.  Flavonoid substrates, dissolved in dimethylformamide, were added after 24 hours 
of initial incubation and incubated 14 days on a rotary shaker at 100 RPM.  Filtrates were 
combined and extracted with isopropanol-ethanol (1:4) and residues were separated over silica 
gel or Sephadex LH-20.  The isolated compounds exhibited a number of possible transformations 
such as hydroxylation, sulfation, glycosylation and methylation with modification occurring 
primarily on the A ring.  The metabolites were tested for antibacterial against Staphylococcus 
aureus, methicillin-resistant Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa 
and Mycobacterium intracellulare.  No antibacterial activity was shown against this set of 
bacteria.  No antifungal activity was revealed against Candida albicans, C. neoformans or 
Aspergillus fumigates.  The compounds were also tested against chloroquine sensitive and 
chloroquine resistant strains of Plasmodium falciparum.   Owing to the lack of established 
activity, structural similarity to icariin and availability for further screening, they were included 
with the plant metabolites.    
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1.3 Experimental Methods 
 
Library generation and ligand preparation 
 Scifinder Chemical Abstracts Service was used to collect compounds from plants: 
Epimedium spp., Lepidium meyenii Walp. (maca), Ginko biloba L., and Ferula hermonis Boiss.  
Varying numbers of compounds were returned in each search.  A set of filters were placed on the 
sets of compounds returned for each plant.  Initial exclusion filters were for isotopes and metal-
containing compounds.  The next set of filters was based on Lipinski-type heuristics to improve 
chances or oral bioavailability.
42
  Compounds outside the range of 100-700 Daltons were 
excluded.  Compounds with greater than 10 hydrogen-bond acceptors or greater than five 
hydrogen-bond donors were excluded.  Compounds with logP outside -10 to 5 range or more 
than 10 freely rotatable bonds were also excluded.  Following the application of these filters, 204 
compounds remained in the set.  These compounds were drawn using ChemDraw and exported 
into .mol2 format so they could be imported to Schrödinger software.  
 Within the Schrödinger software, LigPrep was used to convert chemical structures in 
.mol2 format into three-dimensional models, generate alternate structures, and prepare for 
docking.  For example, LigPrep removes any counter ions in salts and neutralizes charged groups 
by addition or removal of hydrogen atoms.  LigPrep generates various ionization states and 
tautomers for the structures. LigPrep also determines chiral atoms and generates alternate 
isomers and generates low energy conformations for rings within compounds. 
43
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Preparation of protein, ligand and docking procedure  
 The protein structure of PDE5A1 in complex with icariside II was retrieved from 
Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB).
44
  The 
protein was prepared by the Wizard procedure- removing the waters outside of catalytic domain, 
adding any missing hydrogens, and correcting metal ionization states. 
45
  Following this 
preparation, the collection of compounds was placed in Glide Grid for navigation and 
comparison of ligand interactions.  A ligand interaction diagram was produced for icariside II 
and PDE5A1 (see figure below).   Root-mean square deviation was calculated for the true 
PDE5A1 crystal structure complexed with icariside II versus a simulation of the same 
interaction. RMSD score was acceptable at 0.7501, with the greatest variation between flexible 
portions, such as the prenyl side chain (see figure). 
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Figure 11: Icariside II in the catalytic fold of PDE5A1, containing docked icariside II molecule (generated with 
Schrödinger software) 
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Figure 12: Ligand interaction diagram of icariside II in the catalytic fold of PDE5A1. 
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Figure 13: RMSD of icariside II in docked pose, superimposed by atom pairs.  Areas of greatest difference are in 
green boxes. 
Results of Glide Docking 
 Glide was used to dock the collected library into the PDE5A1 structure using basic 
settings.  The HTVS (high-throughput virtual screening) mode was used to reduce the number of 
possible conformations sampled.  The force field used was OPLS 2005.  “Interactive optimized” 
mode was selected for hydrogen-bond states for the preferred tautomer.  The score was a 
negative value based on calculated interactions.  Of the top scoring hits, it was determined that 
all scoring lower (better) than -12 where from the in-house collection of compounds isolated 
from microbial transformation.  The best seven of these compounds available were located and 
prepared to PDE5A testing by Caliper Life Sciences (Perkin Elmer).   
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Figure 14: In silico docking results of selected plant material: The compounds are clustered by source. From left 
to right: F. hermonis, G. biloba, L. meyenii, Epimedium spp. , synthetic compounds, in-house biotransformation 
products  
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Figure 15: Compounds submitted for PDE inhibition assay 
 
Enzyme screening assay   
 Ten compounds were sent to PerkinElmer Discovery Services to conduct inhibition 
screening through phosphodiesterase PDE5A1, in an in vitro biochemical assay at concentrations 
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of 1.0E-4 (100 μM), 1.0E-6 (1 μM), 1.0E-8 (10 nM) in duplicate.  Zaprinast, a 
phosphodiesterase-specific reference compound, was used with the assay.   
 Screening was performed using Caliper LabChip 3000 and a 12- sipper LabChip. In these 
assays, the product and substrate are electrophoretically separated. A microfluidic chip is used to 
measure conversion of fluorescence between substrate and product. The reaction mixture is 
introduced to chip via a capillary sipper where substrate and product are separated.  Reaction is 
monitored by laser-induced fluorescence over time, determining the progress of the reaction.  
 
 
Figure 16: Descriptive scheme of enzyme assay (from PerkinElmer Discovery Services) 
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Table 2: Results of PDE5A1 inhibition assay. 
Percent (%) Inhibition Table, PDE5A1 
Comp. ID 1.E-04 1.E-06 1.E-08 
MJC 1.1 104 43 1 
MJC 1.2 10 6 10 
MJC 1.3 11 12 12 
MJC 1.4 109 21 4 
MJC 1.5 75 23 9 
MJC 1.6 42 20 10 
MJC 1.7 33 17 13 
MJC 1.8 74 27 19 
MJC 1.9 11 -3 -3 
MJC 1.10 77 38 16 
 
 
 
 
1.4 Results and Discussion 
 Mesembrine and mesembrenone were included in this screening set based on their PDE4 
activity.  However, no activity was demonstrated on PDE5A1. Icariin predictably showed good 
inhibition at 1μM concentration.  Compounds 6 and 7 showed weak activity.  Compounds 4, 5, 
8, and 10 demonstrated dose-dependent enzyme inhibition.  It was known that the four sulfated 
compounds may all potentially hydrolyze in DMSO at room temperature based on prior NMR 
experiments.  In this case, activity may be attributable to the products of hydrolysis.  Compound 
4 showed the best activity and it was not previously reported in any phosphodiesterase assays.   
Its dose-response is different from icariin but its overall inhibition warrants further investigation.  
Compound 8 has been subjected to numerous assays but this is the first time to be tested for PDE 
enzyme inhibition.  The desulfated analogue of compound 5 is luteolin, a known, nonspecific 
PDE inhibitor.  Compound 10 is apigenin, also known to inhibit PDE enzymes.  Apigenin 
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previously demonstrated less than one fifth the PDE5 inhibitory activity as luteolin. 
46
  In this 
assay apigenin demonstrates slightly higher PDE inhibition than luteolin.  This may be 
attributable to the presence of sulfate group or a preference within the PDE5 isozymes.  
Compound 9 showed no inhibition.  In this study we successfully applied in silico methods to 
screen potential PDE5A1 inhibitors.  
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CHAPTER 2 
ISOLATION OF METABOLITES FROM TONGKAT ALI 
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2.1 Introduction 
The popular dietary supplement “Tongkat Ali” has a history of traditional use in South 
East Asian countries Malaysia, Indonesia, Vietnam and to a lesser degree in Thailand, 
Cambodia, Myanmar and Singapore.   Specifically, “Tongkat ali” is the Malayian name for a 
group for various members of the Simaroubaceae family which include Eurycoma longifolia 
Jack., Entomophtora apiculata, Polythia bullata and Goniothalamus sp.. 
47
  The most commonly 
studied and used of these is E. longifolia Jack.   The name “Tongkat ali” is Malaysian for 
“walking stick”- because of the plant’s long roots. 48  E. longifolia is commonly referred to as 
Tongkat ali or Long Jack. In Malaysia it has various names including payung ali, penawar pahit, 
pokok syurga and pokok jela among others.
48
  In Vietnam it is referred to as cây-bábinh.
49
  In 
Indonesia it is referred to as pasak bumi.
50
  In Thailand it is known as ian-don and pla-lai-puek. 
51
 
 
Figure 17: Mature E. longifolia tree (left) and root (right). 
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 Traditionally, the roots of this plant are used as a bitter decoction or “coffee”- either in 
combination with coffee and ginseng, or alone.  A native plant of South East Asia, E.longifolia 
has been used primarily for its fever-reducing, anti-malarial and aphrodisiac activities.  There are 
many other secondary applications- for alleviation of general aches, swelling, and dysentery.  
The plant is largely regarded as a revitalizing tonic or adaptogen to promote general healthy 
functioning.  Non-native, western (mostly American) users of the plant have focused on two 
uses: muscle growth and erection enhancement.
52
    
 The phytochemistry of the plant has been examined primarily in Japan, Malaysia and 
China. Characteristic chemical classes identified thus far include: squalene derivatives, canthin-
6-one and β-carboline alkaloids, quassinoids, tirucallane-type triterpenes and biphenyl 
neolignans.
47
  These compounds exhibit cytotoxic, antimalarial, anti-ulcer, antimicrobial, 
antiplasmodial, and antischistosomal activities in various assays.  Plant extracts were also 
evaluated for antidiabetic and aphrodisiac activities in rats. In humans, the effects of E. longifolia 
extracts have been investigated. 
48, 50, 53
  Although limited in participants, studies have shown an 
increase of muscle mass, muscle strength and fat free mass and a decrease in body fat. 
52
   
2.2 Experimental Methods 
 Chemical investigation of the plant was continued to better understand the basis for the 
broad therapeutic potential of E. longifolia’s.  A water extract of Eurycoma longifolia Jack roots, 
purchased from Kaden Biochemicals GMBH (Porgesring 50-22113, Hamburg, Germany) served 
as the crude starting material.  The starting material (250 g) was extracted with methanol (4x 1L) 
to yield a total of 91.41g of extract.  80 grams of this material was fractioned using a normal 
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phase silica column (12 x 120cm) starting with chloroform as mobile phase and increasing 
methanol content by 5% with every 4L.  Fractions were collected by the liter, concentrated, and 
combined on the basis of their TLC profile.  These subfractions were further fractioned by silica 
gel chromatography, leading to the isolation of previously reported compounds. 
2.3 Results and Discussion 
 Two alkaloids were identified: canthin-6-one (2.1) and 9-methoxycanthin-6-one (2.2). 
Two quassinoids were identified laurycolactone A (2.3) and dehydroeurycomalactone (2.4).  The 
only previously unreported compound from the plant is crinosterol (2.5).  The crystalline 
material was isolated using a “hybrid chromatography-crystallization” method to enhance the 
likelihood of attaining crystalline natural products from silica gel chromatography. 
54
  Using a 
chloroform/acetone gradient of increasing polarity (1 to 5%), the collected fractions were 
allowed to slowly dry under the laboratory ventilation hood. The fractions of this column yielded 
four test tubes with crystals.  Three contained crinosterol.  The partial structure was determined  
by 1D and 2D NMR spectroscopy.  The X-ray crystal structure was determined by Henry Valle 
of the University of Mississippi Chemistry Department. 
 
 
37 
 
 
 
Figure 18: ORTEP drawing of crinosterol. 
 
Figure 19: Skeletal formula of crinosterol (2.5) 
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CHAPTER 3 
SYNTHESIS STUDIES TOWARD MESEMBRINE-TYPE ALKALOIDS 
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3.1 Introduction 
 The genus Sceletium is within the iceplant (Aizoaceae, subfamily 
Mesemryanthemoideae) family. The Sceletium genus is comprised of 26 members.
55
  All 
members are endemic to South Africa, primarily within the southwestern region.  These 
succulent plants exhibit a decumbent (creeping) growth pattern with white, yellow or pink 
flowers.
56
      
 The plant contains many cis-3a-aryloctahydroindole alkaloids, which have served as 
synthetic targets for generations of organic chemists.  To date, over 30 alkaloids have been 
isolated from Sceletium plants.  These alkaloids can be grouped into four categories: 3a-aryl-cis-
octahydroindoles, C-seco mesembrine alkaloids, alkaloids bearing 2,3-disubstituted pyridine 
moieties and C- seco A4 group (see Figure 20).
57
  Many of these compounds have served as 
synthetic targets over the years, with the initial syntheses of mesembrine preceding confirmation 
of its biological activity. 
 
Figure 20: The four classes of Sceletium alkaloids 
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 Although the plant is used to settle the stomach, induce bowel movements or as an oral 
anesthetic, the most noteworthy biological effects of the plant are psychoactive.  Traditionally, 
fermented plant material is chewed to produce lucid euphoria which is often followed by 
relaxation or sedation.  Kanna is often consumed in gatherings, not unlike tea or alcohol as a 
social lubricant.  The plant is capable of exerting its effects alone, but many users have made use 
of the plant in combination with cannabis or alcohol.  As of 2013, the plant remains popular as a 
euphoriant with low toxicity.
56
  For this reason, the plant has attracted some interest as a tool to 
treat depression.  Although this formulation has struggled to enter the United States market via 
the Food and Drug Administration’s New Dietary Ingredients Notification, the plant material 
remains available in the US and interest in Sceletium has steadily increased.
58
     
 
Sceletium alkaloids: 
 
Figure 21: Structural similarities between mesembrine and rolipram, a known selective PDE4 inhibitor 
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 In continuation of our efforts in identification of potential phosphodiesterase inhibitors, 
we approached Sceletium alkaloids as natural inhibitors due to their structural similarities with 
rolipram, a known PDE4 inhibitor. A brief literature survey revealed that mesembrine has been 
shown to be active on 5-HT transporter (Ki 1.4nM) as well as PDE4B (IC50 7.8μM).59 Its 
oxidative analogue, mesembrenone showed potent activity against both 5-HT (Ki 27nM) and 
PDE4B (IC50 of 0.5nM) in the nanomolar range. 
59
 Moreover, due to structural resemblance with 
rolipram, Napoletano et al. demonstrated structure-activity relationships of mesembrine 
including the enhancement of PDE4 inhibition by switching the methyl ether group with bulky 
cyclopentylyloxy group.
60
 However, further information of in vitro inhibitory activity of various 
alkaloids from Sceletium is sparse, but there is evidence that cross-talk between cAMP and 
serotonin signaling systems may be involved in depression stemming from decline in cognitive 
function. 
61
 
 
Biosynthesis of Sceletium Alkaloids:  
 The biosynthesis of these alkaloids was explored by Peter Jeffs and co-workers at Duke 
University from 1967-1978.
62
  The alkaloids were first thought to be generated from L-
phenylalanine and L-tyrosine derivatives to create norbelladine which is subject to para-para 
oxidative coupling, generating a crinine-like heterocyclic core structure.  This tetracyclic 
skeleton is repeatedly oxidized at C-7 adjacent to nitrogen, eventually resulting in 
decarboxylation, either before or after O- and N-methylations to form mesembrine.  There is still 
some debate as to the origin of these alkaloids (see Figure 22). 
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Figure 22: Jeffs' original biosynthetic scheme of mesembrine 
 
Earlier synthetic approaches for the construction of mesembrine alkaloid scaffold 
 Mesembrine, mesembrenol and mesembrenone are the only compounds which have been 
screened for CNS target activity in vitro.  Only mesembrine and mesembrenone showed 
appreciable activity at both SERT and PDE4.  Of these two alkaloids, only mesembrine has 
served as a synthetic target.  Its sterically congested architecture with adjacent stereogenic 
centers has served as a ‘proving ground’ of sorts for various synthetic methodologies (see Figure 
23).   
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Figure 23: Starting materials and key intermediates encountered in previous mesembrine syntheses. 
 
 Synthesis of mesembrine would allow for creation of starting material for further 
investigation of structure-activity relationships.  There have been approximately 40 published 
total and formal syntheses of mesembrine, the first of which was demonstrated in 1965.
63
 To 
assess the potential inhibitory activities of novel analogues based on the mesembrine scaffold, 
we have undertaken the total synthesis of mesembrine whose retrosynthetic analysis shown 
below. In our proposed synthetic approach, the primary challenge posed was the establishment of 
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asymmetry at the all-carbon quaternary center.  This route considered the possibility of using a 
chiral auxiliary in the early stage to induce the required chirality.  The chosen auxiliary was a 
readily available oxazolidinone derived from phenylalanine.  The use of oxazolidinone chiral 
auxiliaries was pioneered by Evans and co-workers in 1981.  The approach was explored 
throughout the 1980s to provide scalable, diastereoselective Michael additions, 
cyclopropanations, alkylations, aldol condensations and Diels-Alder reactions.
64
  Despite this 
capacity to selectively generate diastereomers, it had not been employed to create a quaternary 
stereogenic center in a system similar to mesembrine. 
 
Figure 24: Initial mesembrine retrosynthetic route 
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3.2 Experimental Approach and Discussion 
 
 
 
 
 
 
Table 3: Alkylation of (S)-4-benzyl-3-[2-(4-methoxyphenyl)acetyl]oxazolidin-2-one
 
Alkyl halide Conditions Yield 
Bromo acetonitrile LiHMDS/THF, 0oC to rt 80% 
Allyl bromide LiHMDS/THF, 0oC to rt 30% 
Methyl vinyl ketone LiHMDS/THF, 0oC to rt <1% 
Methyl vinyl ketone NaHMDS/THF, 0oC to rt <1% 
Methyl vinyl ketone DIPEA, TiCl4/ DCM, -40oC 67% 
 
 
 
 
 
 
 
 
46 
 
 
 
 
 
 
 
Alkyalation-2: 
 
 
Figure 25: Reactions attempted to create benzylic stereogenic center 
 
 The initial plan was to use 4-methoxyphenylacetic acid as starting material since it was 
readily available from previous work in our group on the synthesis of phytoestrogens, with the 
second methoxy group to be added at the end by oxidation.  The first alkylation was attempted 
using bromo acetonitrile following deprotonation by lithium bis(trimethylsilyl)amide (LiHMDS).  
As anticipated, the reaction worked without any difficulty and yielded the required product in 
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good yields. Similarly, allyl bromide furnished the corresponding alkylated product in moderate 
yield. When the lithium enolate was subjected to Michael addition with methyl vinyl ketone, 
complex products were observed.  Many attempts were made to create the quaternary center, 
using different reagents and conditions (see Table 3, alkylation 2), but none of these reactions 
were successful. At this point the synthetic plan was modified to effect the initial substitution 
with methylvinyl ketone (MVK), and then to alkylate with two carbon chain alkylating agents. 
An alternate strategy would require reductive removal of the chiral auxiliary and working toward 
the cyclopentene synthetic intermediate of Taber et al. (Figure 26). 
65
  
 
Figure 26: Synthetic scheme of Taber et al. (2001) 
 
 This reaction was based on the work of Evans in which he explored asymmetric Michael 
additions using TiCl4 and diisopropylethylamine (Hunig’s base/ DIPEA).
66
  Initially the reaction 
48 
 
 
generated approximately 1% product, enough to verify by 
1
H-NMR.  By carefully screening of 
various temperatures and addition sequence, the yield was improved to 67%.  This improvement 
seemingly corresponded to slower addition of MVK, and lower enolization temperature (-40
o
C 
instead of -25
o
C). 
 Next, the ketone was protected as ketal and the resulting amide reduced to the 
corresponding alcohol.  The goal was to then protect the resulting alcohol and subject to 
intramolecular alkylidene insertion reaction pioneered by Taber to cyclize into a cyclopentene 
ring with stereogenic quaternary center.  Due to time constraints, the envisioned synthetic 
sequence was halted at this stage. 
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Figure 27: Compounds generated 
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NMR AND X-RAY DATA OF COMPOUNDS ISOLATED FROM TONGKAT ALI 
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Figure 17: 
1
H NMR spectrum of 2.1 (canthin-6-one) 
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Figure 18:  
1
H NMR spectrum of 2.2 (9-methoxycanthin-6-one) 
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Figure 19: 
1
H NMR spectrum of 2.3 (dehydroeurycomalactone) 
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Figure 20: 
1
H NMR spectrum of 2.4 (laurycolactone A) 
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Figure 21: Wireframe model of 2.5 (crinosterol) molecules in unit cell to clarify three-dimensional structure 
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Figure 22: 
1
H NMR spectrum of 2.5 (crinosterol) 
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Figure 23: 
13
C NMR spectrum of 2.5 (crinosterol) 
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(S)-4-Benzyl-3-[2-(4-methoxyphenyl)acetyl]oxazolidin-2-one (Compound 3.1): Prepared 
according to Heemstra et al., 2006. 
67
   [α]D= 63.5 (c=0.5, CHCl3),    IR(cm
-1
): 2922, 1771, 1693, 
1611, 1510, 1387, 1353, 1243, 1175, 1102, 1030  
1
H NMR: 
1
H NMR (400 MHz, CDCl3) δ 7.34 
– 7.25 (m, 5H), 7.15 (dd, J = 7.3, 2.0 Hz, 2H), 6.94 – 6.88 (m, 2H), 4.68 (ddt, J = 10.2, 6.8, 3.3 
Hz, 1H), 4.34 – 4.14 (m, 1H), 3.82 (s, 2H), 3.27 (dd, J = 13.4, 3.0 Hz, 1H), 2.78 (dd, J = 13.3, 
9.4 Hz, 1H) 
13
C NMR (101 MHz, CDCl3) δ 171.56, 158.83, 153.42, 135.18, 130.84 (2C), 129.45 
(2C), 128.93 (2C), 127.32, 125.54, 114.04 (2C), 66.13, 55.30, 40.70, 37.72   
 
 
(R)-4-[(S)-4-benzyl-2-oxooxazolidin-3-yl]-3-(4-methoxyphenyl)-4-oxobutanenitrile 
(Compound 3.2): Compound 3.1 (3.25 g, 10.0 mmol) was dissolved in 35 ml of dry 
tetrahydrofuran.  After cooling the solution to 0
o
C, LiHMDS (12 ml, 1.0M in THF) was added 
dropwise.  After 25 minutes, bromo acetonitrile (0.84 ml, 12 mmol) was added.  After one hour, 
the reaction was quenched with saturated aqueous ammonium chloride solution.  After filtration 
and concentration under reduced pressure, the material was purified by silica gel 
chromatography using hexanes and ethyl acetate (3:1). The concentrated product was an amber 
oil, which solidified on standing. The material was re-crystallized with warm hexane and ethyl 
acetate to form clear crystals.  [α]D= 176.8 (c=0.5, CHCl3), IR (cm
-1
): 2989, 2925, 2849, 1778, 
1678, 1608, 1511, 1385, 1253, 1217, 1178, 1111 
1
H NMR:
1
H NMR (400 MHz, CDCl3) δ 7.38 – 
7.18 (m, 5H), 6.86 (d, J = 8.7 Hz, 2H), 5.35 – 5.26 (m, 2H), 4.60 (ddt, J = 9.8, 5.4, 2.6 Hz, 1H), 
4.17 – 3.98 (m, 2H), 3.77 (s, 3H), 3.34 (dd, J = 13.5, 3.2 Hz, 1H), 3.06 (dd, J = 16.6, 8.2 Hz, 
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1H), 2.88 (d, J = 9.5 Hz, 1H), 2.78 (dd, J = 16.6, 6.8 Hz, 1H).
13
C NMR: (101 MHz, CDCl3) δ 
171.09, 159.73, 152.43, 134.87, 129.44 (4C), 129.04 (2C), 127.48, 127.18, 117.83, 114.54 (2C), 
66.15, 55.78, 55.29, 45.01, 37.77, 22.26  ESI-HRMS: calcd. C21H21N2O4 m/z 365.1459 [M+H]
+
; 
found m/z 365.1432 
 
(R)-1-[(S)-4-Benzyl-2-oxooxazolidin-3-yl]-2-(4-methoxyphenyl)hexane-1,5-dione 
(Compound 3.3): Compound 3.2 (3.25g was dissolved in anhydrous dichloromethane at room 
temperature under argon an atmosphere.  The solution was cooled to -50
o
C, and 
diisoproylethylamine (Hünig’s base) was added.  This mixture was stirred at -50oC for 15 
minutes, followed by addition of TiCl4 solution (1.0M in DCM), and stirred for one hour at -
50
o
C.  A dilute solution of methyl vinyl ketone in anhydrous dichloromethane (1.13 ml MVK/ 40 
ml dicholoromethane) was added dropwise. The reaction was quenched when bath temperature 
reached 0
o
C (~45 minutes) with saturated sodium/potassium tartrate (Rochelle salt) solution.  
After filtering and concentration under reduced pressure, the material was purified by silica gel 
chromatography using hexanes and ethyl acetate (3:1) yielding a clear oil. [α]D= 84 (c=0.5, 
CHCl3) IR (cm
-1
):  2930, 1773, 1691, 1607, 1509, 1450, 1367, 1244, 1178, 1106, 1029 
1
H NMR 
(500 MHz, CDCl3) δ 7.48 – 7.21 (m, 5H), 6.87 (d, J = 8.7 Hz, 2H), 5.10 – 4.88 (m, 2H), 4.60 (t, 
J = 8.6 Hz, 2H), 4.34 – 4.01 (m, 7H), 3.81 (s, 5H), 3.38 (dd, J = 13.3, 3.0 Hz, 3H), 2.81 (dd, J = 
13.3, 9.8 Hz, 2H), 2.54 – 2.28 (m, 12H), 2.26 – 2.00 (m, 11H), 1.28 (t, J = 7.1 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 207.89, 173.82, 159.05, 152.90, 135.33 (2C), 129.78 (2C), 129.43 
(2C), 128.98, 127.37, 114.10 (2C), 65.92, 55.81, 55.25, 46.99, 41.21, 38.05, 29.92, 27.75. ESI-
HRMS: calcd. C23H26NO5 m/z  396.1733 [M+H]
+
; found m/z 396.1739 
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(S)-4-Benzyl-3-[(R)-2-(4-methoxyphenyl]-4-(2-methyl-1,3-dioxolan-2-
yl)butanoyl)oxazolidin-2-one (Compound 3.4): Compound 3.3 was dissolved in benzene at 
room temperature. To the round-bottom flask, ethylene glycol and  para-toluenesulfonic acid 
were added.  A Dean-Stark apparatus was used and reaction was refluxed for five hours.  The 
reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with 
diethyl ether. This organic material was concentrated under reduced pressure and purified by 
silica gel chromatography using hexanes and ethyl acetate (3:1) with triethylamine (0.2% of total 
volume) was added to mobile phase.  The overall yield was 97% in the form of a clear oil.; [α]D= 
76 (c=0.5, CHCl3) IR (cm
-1
): 2922, 2836, 1774, 1692, 1607, 1509, 1452, 1375, 1246, 1179, 
1102, 1031 
1
H NMR (400 MHz, CDCl3) δ 7.29 (m, 7H), 6.84 (d, J = 7.6 Hz, 2H), 4.98 (t, J = 7.4 
Hz, 1H), 4.57 (t, J = 7.4 Hz, 1H), 4.16 – 3.94 (m, 6H), 3.77 (s, 3H), 3.36 (d, J = 12.5 Hz, 1H), 
2.78 (dd, 1H), 2.21 (ddd, J = 17.3, 11.6, 5.5 Hz, 1H), 2.01 – 1.90 (m, 1H), 1.67 (m, 1H), 1.57 
(1H) 1.31 (s, 3H) 
13
C NMR (101 MHz, CDCl3) δ 174.19, 158.87, 152.94, 135.41, 130.52, 
129.70 (2C), 129.42 (2C), 128.99, 128.93 (2C), 127.30, 113.99 (2C), 109.71, 65.79, 64.60, 
55.76, 55.21, 47.56, 38.03, 36.57, 28.54, 23.84 ESI-HRMS: calcd. C25H30NO6 m/z 440.1995 
[M+H]
+
; found m/z 440.1982 
 
(R)-2-(4-Methoxyphenyl)-4-(2-methyl-1,3-dioxolan-2-yl)butan-1-ol (Compound 3.5): 
Compound 4.4 (0.5g, mmol) was dissolved in tetrahydrofuran at room temperature. The solution 
was cooled to 0
o
C before adding 100 mg of lithium aluminum hydride. The solution was allowed 
to warm to room temperature and was stirred overnight. After 12 hours, the reaction mixture was 
quenched with saturated aqueous ammonium chloride solution, extracted with ethyl acetate and 
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purified by column chromatography to yield alcohol 3.5 in greater than 95% yield (255 mg). 
[α]D= 5 (c=0.5, CHCl3) IR (cm
-1
): 3409 (br), 2935, 2877, 1746, 1609, 1510, 1458, 1375, 1375, 
1299, 1244, 1177, 1136, 1031  
1
H NMR (400 MHz, CDCl3) δ 7.05 (d, J = 8.6 Hz, 2H), 6.79 (d, J 
= 8.6 Hz, 2H), 3.85 – 3.74 (m, 5H), 3.71 (s, 3H), 3.66 – 3.58 (m, 2H), 2.92 (t, J = 11.3 Hz, 1H), 
1.62 – 1.38 (m, 4H), 1.19 (s, 3H) 13C NMR (101 MHz, CDCl3) δ 158.38, 133.91, 128.94 (2C), 
114.09 (2C), 109.95, 64.60, 64.54, 63.67, 55.23, 47.77, 36.74, 26.28, 23.79  ESI-HRMS: calcd. 
C13H18O2 m/z  205.1234 [M-H]
+
; found m/z 205.1180 
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APPENDIX C: 
MESEMBRINE SYNTHETIC INTERMEDIATES IR AND NMR SPECTRA 
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Figure 24: IR Spectrum (neat) of 3.1 
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Figure 25: 
1
H NMR spectrum of 3.1 
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Figure 26: 
13
C NMR spectrum of 3.1 
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Figure 27: IR Spectrum (neat) of 3.2 
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Figure 28:  
1
H NMR spectrum of 3.2 
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Figure 29: 
13
C NMR spectrum of 3.2 
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Figure 30: IR spectrum of 3.3 
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Figure 31: 
1
H NMR spectrum of 3.3 
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Figure 32: 
13
C NMR spectrum of 3.3 
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Figure 33: IR Spectrum of 3.4 
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Figure 34: 
1
H spectrum of 3.4 
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Figure 35: 
13
C spectrum of 3.4 
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Figure 36: IR Spectrum (neat) of 3.5 
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Figure 37: 1H NMR spectrum of 3.5 
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Figure 38: 13C NMR spectrum of 3.5
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